Recently, the proteomic panel was expanded to eight signature peptide biomarkers to screen for five molecularly defined IEI including adenosine deaminase (ADA) deficiency, dedicator of cytokinesis 8 (DOCK8) deficiency, X-Linked chronic granulomatous disease (XL-CGD), WAS, and XLA [60]. This evidence concerns the gene ADA and chronic granulomatous disease.